Skip to main content

Table 15 The cost-effectiveness analysis in the 24-month period (the incidence of normal blood glucose)

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group C (yuan) E (%) C/E ΔC/ΔE
The treatment group 41367830.8 20.3 2037824.8 −307040.6
The control group 37529823.2 32.8 1144201.0  
  1. C the total costs, C/E the cost-effectiveness ratio, ΔC/ΔE the incremental cost-effectiveness ratio